Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside the body in patient-derived cells (ex vivo). Its pipeline targets conditions with significant unmet medical need, including transthyretin (ATTR) amyloidosis, hereditary angioedema, sickle cell disease, and various immuno-oncology indications. Intellia Therapeutics Inc. collaborates with major pharmaceutical partners to advance and potentially scale its therapeutic programs, leveraging shared expertise in drug development and commercialization. Operating within the healthcare and biotechnology sector, the company plays a prominent role in the emerging field of gene editing, where its technologies are used to explore one-time, precisely targeted interventions for serious genetic disorders. Intellia Therapeutics Inc. is headquartered in Cambridge, Massachusetts, a key hub for life sciences and biotech innovation.